Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”

Golubovskaya, Vita

doi:10.3390/cancers15205053

Cancers

2023

DOI: 10.3390/cancers15205053

|View full text |Cite

Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”

Vita Golubovskaya

Abstract: This Special Issue in Cancers, “Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer”, includes interesting reports and reviews on cell therapies and bispecific antibodies [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies

Bauvois,

Nguyen-Khac,

Merle-Béral

et al. 2024

Biochimie

View full text Add to dashboard Cite

CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies

Bauvois,

Nguyen-Khac,

Merle-Béral

et al. 2024

Biochimie

View full text Add to dashboard Cite

Advances and challenges in anti-cancer vaccines for multiple myeloma

Abdollahi,

Norseth,

Schjesvold

2024

Front. Immunol.

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematological cancer marked by plasma cell accumulation in the bone marrow. Despite treatment advancements, MM remains incurable in most patients. MM-associated immune dysregulation fosters disease progression, prompting research into immunotherapy to combat the disease. An area of immunotherapy investigation is the design of myeloma vaccine therapy to reverse tumor-associated immune suppression and elicit tumor-specific immune responses to effectively target MM cells. This article reviews vaccine immunotherapy for MM, categorizing findings by antigen type and delivery method. Antigens include idiotype (Id), tumor-associated (TAA), tumor-specific (TSA), and whole tumor lysate. Myeloma vaccination has so far shown limited clinical efficacy. However, further studies are essential to optimize various aspects, including antigen and patient selection, vaccine timing and sequencing, and rational combinations with emerging MM treatments.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”

Abstract: This Special Issue in Cancers, “Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer”, includes interesting reports and reviews on cell therapies and bispecific antibodies [...]

Cited by 2 publications

References 50 publications

CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies

CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies

Advances and challenges in anti-cancer vaccines for multiple myeloma

Contact Info

Product

Resources

About